PRP for Diminished Ovarian Reserve
(PRP4POA Trial)
Trial Summary
What is the purpose of this trial?
Consenting women with evidence of poor ovarian reserve will be randomly assigned to treatment with either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP).
Will I have to stop taking my current medications?
The trial requires that you stop taking Aspirin or Motrin for one week before treatment. If you are on anticoagulant or antiaggregant treatments, you may not be eligible to participate.
What data supports the effectiveness of this treatment for diminished ovarian reserve?
Research suggests that injecting platelet-rich plasma (PRP) into the ovaries may help improve ovarian function and increase the chances of pregnancy in women with low ovarian reserve. Studies have shown that PRP can positively impact markers of ovarian reserve, oocyte (egg) quality, and embryo yield, potentially leading to better outcomes in fertility treatments.12345
Is PRP therapy safe for humans?
How is PRP treatment different from other treatments for diminished ovarian reserve?
PRP treatment is unique because it involves injecting a concentrated portion of the patient's own blood (platelet-rich plasma) directly into the ovaries, which may help improve ovarian function and increase pregnancy chances. This approach is novel compared to traditional fertility treatments and carries a lower risk of disease transmission and allergic reactions since it uses the patient's own blood.12358
Research Team
David H Barad, MD MS
Principal Investigator
Center for Human Reproduction
Eligibility Criteria
Women under 45 with poor ovarian reserve, who haven't taken Aspirin or Motrin for a week, want to get pregnant through IVF, have had fewer than 6 eggs from past treatments, and have specific hormone levels (FSH > 12 and AMH < 1.0). It's not for those over age 45 or with certain blood diseases, clotting disorders, cancer, infections like sepsis, or autoimmune conditions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Platelet Rich Plasma (PRP) or Platelet Poor Plasma (PPP) for ovarian function improvement
Follow-up
Participants are monitored for safety and effectiveness after treatment, including embryo production and hormone levels
Treatment Details
Interventions
- PPP - Platelet Poor Plasma
- PRP - Platelet Rich Plasma
PPP - Platelet Poor Plasma is already approved in United States, European Union for the following indications:
- Coagulation testing
- Orthopedic surgery
- Cosmetic surgery
- Wound healing
- Coagulation testing
- Orthopedic surgery
- Cosmetic surgery
- Wound healing
Find a Clinic Near You
Who Is Running the Clinical Trial?
Center for Human Reproduction
Lead Sponsor